Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study

Overview of attention for article published in OncoTargets and therapy, June 2015

Altmetric Badge

Citations

dimensions_citation: 28 Dimensions

Readers on

mendeley: 28 Mendeley

Summary Dimensions citations

So far, Dimensions has found 28 publications that cite this research output.

28

The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.

Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies

Article in BMC Cancer (March 2024)

Looking into the toxicity potential and clinical benefits of tyrosine kinase inhibitors (TKIs)

Book chapter (January 2024)

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy

Article in Cancer Research and Treatment (November 2022)